Pulmonology

Latest News
July 18th 2025

Lung Transplant Referrals Lag for High-Risk Patients With PAH

July 9th 2025

Global Study Warns of Rising PAH Burden

June 11th 2025

TPIP a Potential Game-Changer for Prostanoid Therapy in PAH

June 7th 2025

Patients With ILD in Rural Areas Face Barriers to Care

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

Video Interviews
View All
October 9th 2024

Dr Daniel Howell Details the Current Types of Therapies for Effective COPD Management

October 8th 2024

Dr Jonathan Kurman Outlines Emerging Bronchoscopic Therapies for COPD

October 7th 2024

Dr Krunal Patel: New Research Explains the Impact of Early Mechanical Thrombectomy in Acute PE

October 7th 2024

Dr Scott Manaker Looks to the Future of Physician Compensation at CHEST 2024

October 3rd 2024

The Spectrum of Pulmonary Disease: Dr Parth Rali Highlights CHEST 2024 Agenda

October 1st 2024

Dupilumab Improves Lung Function, Type 2 Inflammation in COPD

More News

PAH X-ray with pen | Image credit: Dzmitry – stock.adobe.com
May 30th 2025

Sotatercept for PAH Maintains Safety, Reduced Mortality in Long-Term Follow-Up

Hayden E. Klein
The pulmonary arterial hypertension (PAH) drug preserved its safety profile at 2.5 years of treatment and continued to reduce mortality compared with placebo.
Transplant-free survival from the time of right-heart catheterization was also significantly longer in the dual therapy group. | Image Credit: mi_viri - stock.adobe.com
May 15th 2025

Dual Therapy Appears to Benefit Patients With Pulmonary Fibrosis, Pulmonary Hypertension

Jared Kaltwasser
The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.
Heartbeat EKG | Image Credit: © Tima-stock.adobe.com
May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

Maggie L. Shaw
Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).
Walking analysis | Image Credit: © Microgen-stock.adobe.com
May 6th 2025

18MWT Contributes Valuable Feedback in Setting of PAH

Maggie L. Shaw
The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial hypertension (PAH), enhancing traditional assessment methods.
Fitness device | Image Credit: © anatolir-stock.adobe.com
April 21st 2025

Wearable Tech Has Potential to Indicate PAH-Related Decline

Maggie L. Shaw
For this analysis, outcomes were compared between individuals who had pulmonary arterial hypertension (PAH) and healthy controls by using Fitbit-derived data over 12 weeks and then at a 1-year follow-up.
A new report suggests that patients with PAH consistently report higher symptom burden than their physicians do for their condition | image credit: bongkarn - stock.adobe.com
December 30th 2024

People With PAH Report Higher Symptom Burden Than Their Physicians

Jared Kaltwasser
Patients and physicians agree about which symptoms have the biggest impact on patients’ quality of life.
Top 5 PAH Articles of 2024
December 29th 2024

Top 5 Most-Read PAH Articles of 2024

Julia Bonavitacola
The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes on hypertension, and how diagnosis time affects outcomes.
Lung analysis concept | image credit: Shahidah - stock.adobe.com
December 8th 2024

Nanoparticle Delivery Holds Promise for Treatment of PAH

Karen Jacobson-Sive
Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.
Chest X-ray for lung health assessment | image credit: Radiographys - stock.adobe.com
December 5th 2024

Slow, Steady Advances: Noninvasive Diagnosis of PH in ILD Populations

Gayle Turim Dickstein
Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help improve the landscape.
Despite lacking long-term data, vaping is not risk free | image credit: fotofabrika - stock.adobe.com
November 5th 2024

Vaping Risks: Known and Unknown

Kyle Munz
Although vapes have not been around long enough to yield long-term safety data, known risks associated with their ingredients and reported lung injuries suggest the dangers of this habit.
PAH concept | image credit: Ahmad - stock.adobe.com
October 23rd 2024

Early Use of Triple Oral Therapy May Lower Hospitalizations for PAH

AJMC Contributor
The comparative effectiveness study found that the addition of selexipag (Uptravi) to double oral therapy (DOT) reduced the risk of patients being hospitalized or having their disease progress.
Zeina Morcos, MD
October 10th 2024

Late-Breaking Data Suggest AI Diagnosis of Pulmonary Embolism Could Be the Future: Dr Zeina Morcos

Giuliana Grossi
CHEST 2024 late-breaking data showcased the potential of AI-based systems in diagnosing and managing pulmonary embolism.
Mobility reduction may be an early sign of PAH | image credit: PrusarooYakk - stock.adobe.com
October 9th 2024

A Call for Consistent Digital Mobility Measurement Protocols in PAH

Gayle Turim Dickstein
As more researchers utilize digital technology to measure mobility in pulmonary arterial hypertension (PAH), a team calls for consistent protocols to make outcomes as meaningful as possible to patients and clinicians
Human lungs on scientific background | Image Credit: © Crystal light - stock.adobe.com
September 27th 2024

Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH

Gwen Mergian
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.
Months after the FDA's approval of sotatercept for treating PAH, the drug has gained European approval | image credit: wladimir1804 - stock.adobe.com
September 11th 2024

Sotatercept Gains European Approval for PAH for Use With Other Treatments

AJMC Contributor
The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial hypertension (PAH).
FDA | image credit: Araki Illustrations - stock.adobe.com
September 5th 2024

Inhaled PAH Therapy Gets Tentative Go-Ahead From FDA

Jared Kaltwasser
The tentative approval cannot take effect because a competing product was granted market exclusivity.
CPAP therapy can reduce the risk of hypertension during pregnancy | image credit: sokko_natalia - stock.adobe.com
August 24th 2024

CPAP Treatment Can Significantly Reduce Hypertensive Adverse Outcomes in Pregnancy

Gayle Turim Dickstein
When women with obstructive sleep apnea (OSA) carrying high-risk pregnancies collaborate with their health care providers to find the best individualized continuous positive airway pressure (CPAP) treatment, their risks of gestational hypertension and preeclampsia may drop appreciably
COPD animation | Image Credit: peterschreiber.media - stock.adobe.com
August 20th 2024

Study: Most Patients With COPD Remain Untreated Following Initial Diagnosis

Brooke McCormick
Most patients with chronic obstructive pulmonary disease (COPD) remain untreated after diagnosis, leading to frequent exacerbations.
Clinician listening to child's heartbeat | image credit: Maria Sbytova - stock.adobe.com
August 19th 2024

Circulating HMGB1 Not a Reliable Biomarker in Pediatric PAH

Jared Kaltwasser
Though circulating high mobility group box-1 levels appear to be a biomarker for pulmonary arterial hypertension (PAH) in adults with congenital heart disease, the same is not true in pediatric patients.
Definition of malnutrition | Image Credit: Feng Yu - stock.adobe.com
August 15th 2024

Malnutrition in Older Patients With COPD Linked to Higher Hospital Readmission Rates

Brooke McCormick
Malnutrition significantly increases the 180-day hospital readmission rates among patients 65 years or older with chronic obstructive pulmonary disease (COPD), highlighting the importance of monitoring and improving their nutritional status.
Fruits and vegetable intake provides proven benefits for patients with hypertension | image credit: peangdao - stock.adobe.com
August 13th 2024

Fruit and Vegetables Outperform Medication and Baking Soda to Treat Hypertension 

Karen Jacobson-Sive
Patients with hypertension-related chronic kidney disease who increased daily fruit and vegetable consumption showed improved cardiovascular health and reduced blood pressure compared with participants who added baking soda to their diet or who received pharmacological-only treatment.
hypertension in pregnancy | Image Credit: peopleimages.com-stock.adobe.com
August 4th 2024

Hypertensive Disorders of Pregnancy on the Rise in Canada

Gayle Turim Dickstein
Researchers don’t fully understand why these disorders are increasing, but they declare that finding out should be a top priority.
representation of pulmonary hypertension | Image Credit: Angelov-stock.adobe.com
July 31st 2024

Early Treatment May Help Prevent PAH in High-Risk Patients

AJMC Contributor
New data from the single-center, open-label extension EDITA-ON study suggest that early treatment for pulmonary arterial hypertension (PAH) could benefit patients with systemic sclerosis and early pulmonary vascular disease.
doc reviewing lung report | Image Credit: meeboonstudio-stock.adobe.com
July 28th 2024

High Costs, Hospitalizations Linked to PH, ILD

Karen Jacobson-Sive
The hospitalization rate for patients with pulmonary hypertension (PH) and interstitial lung disease (ILD) doubled over a 2-year period, and total health care costs more than doubled over the same period.
pulmonary hypertension graphic | Image Credit: Dzmitry - stock.adobe.com
July 24th 2024

CTEPH Treatment, Management Varies Widely Across Globe

Jared Kaltwasser
A new report shows wide variability in terms of which patients with chronic thromboembolic pulmonary hypertension (CTEPH) are deemed eligible for pulmonary endarterectomy and balloon pulmonary angioplasty.
Hospital room | Image Credit: catinsyrup - stock.adobe.com
July 18th 2024

COPD Linked to Increased Mortality, Hospitalization Risk in Patients With HFpEF

Brooke McCormick
Chronic obstructive pulmonary disease (COPD) significantly heightens the risk of mortality and hospitalization in patients with heart failure with preserved ejection fraction (HFpEF).
doc measuring BP in pregnany woman | Image Credit: Andrey Popov-stock.adobe.com.jpeg
July 17th 2024

Proteomics Promise: Not Yet Realized in Early Prediction of HDP

Gayle Turim Dickstein
Investigators hoped to use large-scale proteomics to help predict hypertensive disorders of pregnancy (HDP), using blood proteins obtained from individuals in their first trimester of pregnancy—but success has been elusive.
Doc taking BP | Image Credit: Prostock-studio-stock.adobe.com
July 10th 2024

Integrating Maternal BP Checks in Pediatric Visits Enhances Outcomes

Kimberly Rath, PharmD
A quality improvement program found that maternal blood pressure (BP) screening during early well-child visits significantly improves the early detection and management of postpartum hypertensive disorders.
Pregnant monitoring BP | Image Credit: alfa27-stock.adobe.com
June 27th 2024

Hypertension Disorders of Pregnancy Largely Persist in the Postpartum Period

Karen Jacobson-Sive
More than 80% of pregnant patients with new-onset hypertensive disorder remain hypertensive after hospital discharge.
Asian man with hypertension | Image Credit: jeffy1139-stock.adobe.com
June 18th 2024

Community Practitioner–Led Hypertension Program Yields Strong Results

Jared Kaltwasser
A Chinese study shows hypertension management led by nonphysicians can be safe and effective.
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo